Blockchain has already infiltrated the drug industry, from tracking supply chain to information management system to cryptocurrencies to pay people for their genomic sequencing. But now Agenus Inc. is looking to use the tracking technology to help fund drug development. The company announced plans to launch a Biotech Electronic Security Token (BEST), which will be tied to its anti-PD-1 antibody, AGEN-2034.
Spun out of work from Jan Kraus' lab at the University of Colorado in 2013, Orphan Technologies Ltd. has moved its first drug into the clinic. The Lexington, Mass.-based company is part of the Neopharm group, of Petach Tikva, Israel, a private company owned by a single family.
The global pharmaceutical market will surpass $1.5 trillion by 2023, according to a new report from Iqvia Institute for Human Data Science. That works out to a compounded annual growth rate of 3 percent to 6 percent over the next five years, which is, unfortunately, a slowdown from the 6.3 percent growth the industry has experienced over the past five years.
The global pharmaceutical market will surpass $1.5 trillion by 2023, according to a new report from Iqvia Institute for Human Data Science. That works out to a compounded annual growth rate of 3 percent to 6 percent over the next five years, which is, unfortunately, a slowdown from the 6.3 percent growth the industry has experienced over the past five years.
Bernard Gilly, co-founder and CEO of Gensight Biologics SA, was upbeat about the readout of Gensight's phase III Rescue study testing its gene therapy, GS-010, in patients with 11778-ND4 Leber hereditary optic neuropathy (LHON).
The global pharmaceutical market will surpass $1.5 trillion by 2023, according to a new report from Iqvia Institute for Human Data Science. That works out to a compounded annual growth rate of 3 percent to 6 percent over the next five years, which is, unfortunately, a slowdown from the 6.3 percent growth the industry has experienced over the past five years.
Following up on its 2017 $23.5 million series A financing, Lyndra Therapeutics Inc. secured $55 million in a series B round to support the development of its long-acting therapies. All of the previous investors resubscribed, while Hopu Investments, Gilead Sciences Inc., Invus, the Bill & Melinda Gates Foundation and Orient Life joined their ranks. (See BioWorld Today, April 14, 2017.)
